FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283711468> ?p ?o ?g. }

• W4283711468 endingPage "987" @default.
• W4283711468 startingPage "986" @default.
• W4283711468 abstract "Background Juvenile Arthritis Disease Activity Score (JADAS) has been developed as a composite disease activity score specific to Juvenile idiopathic arthritis (JIA). Evaluation of disease activity with a composite measure associated with subsequent changes in structural damage of joints and physical function is necessary for the proper management of Rheumatoid Arthritis (RA) with treat-to-target strategy, and this concept should be considered for patients with JIA in transition and adulthood as well. However, the usefulness of JADAS-27 and other composite measures for RA in these patients has been scarecely investigated. Additionally, JADAS-27 is unfamiliar to non-pediatric rheumatologists. Objectives We aimed to investigate an optimal composite score for disease activity in adult JIA from the viewpoint of the subsequent changes in physical function. Methods Patients diagnosed with JIA with the following conditions were enrolled: 1) disease onset at age < 18 years; 2) registered in the IORRA database for the first time between 2000 and 2020; and 3) ≥18 years old at the time of IORRA registration. The baseline of each patient was their initial entry into the IORRA database. The Simplified Disease Activity Index (SDAI), Disease Activity Score using 28 joints (DAS28), and JADAS-27 were compared. The patients were stratified into four disease activity categories: remission/inactive disease, low disease activity, moderate disease activity, and high disease activity according to mean disease activity scores in each index during the first year from baseline, and mean changes in J-HAQ (mean ΔJ-HAQ) during 2 years from baseline in each disease activity group were estimated using the linear mixed effect model to account for correlations of repeated measures without filling in the missing data after adjusting for sex, age, and disease duration. Results We included 294 eligible individuals (median age at onset, 14.0 years; rheumatoid factor positive in 64.7%). The median age at baseline and disease duration was 33.8 (24.1–47.7) years and 21.0 (11.0–34.0) years, respectively. The J-HAQ was completed in all 294 patients, and 171 (58.1%) had a score of less than 0.5 at baseline, which is defined as functional remission. During the 2-year observation period, the median J-HAQ of all patients remained unchanged. There was a trend toward improvement in disease activity over time in all three composite scores. Some differeces were obsered across the three indeces: a higher proportion of patients with high disease activity and a lower proportion of patients in remission/inactive disease were observed with JADAS-27 versus SDAI and DAS28. A significant increasing trend of the estimated mean ΔJ-HAQ at 2 years after baseline was observed along with an increase in the mean disease activity during the first year measured using DAS28 (p = 0.01) and SDAI (p = 0.018), but not using JADAS-27 as shown in Table 1. Table 1. Association of the mean disease activity categories during the first year after baseline and mean changes in J-HAQ during the two years after baseline (n = 294 ) SDAI DAS28 JADAS-27 Remission/inactive disease 0.019 [−0.190, 0.228] 0.053 [0.024, 0.130] 0.081 [−0.072, 0.234] LDA 0.091 [−0.150, 0.332] 0.102 [−0.013, 0.217] 0.054 [−0.102, 0.210] MDA or HDA 0.155 [−0.286, 0.596] 0.136 [0.030, 0.242] 0.087 [0.022, 0.152] p-value for trend 0.019 0.010 0.115 (Data are expressed as J-HAQ [95% confidence interval]. P-value less than 0.05 indicate a significant trend of the mean ΔJ-HAQ during the two years after baseline. LDA low disease activity; MDA moderate disease activity; HDA high disease activity) Conclusion Disease activity measured using SDAI and DAS28, but not using JADAS27, was significantly associated with subsequent changes in physical function in transitional and adult patients with JIA. This study support the use of SDAI and DAS28, but not JADAS27, in assessing disease activity in these patients to adjust treatments for preventing future deterioration of physical function. Disclosure of Interests Takako Miyamae: None declared, Eisuke Inoue Speakers bureau: EI has received lecture fees or consulting fees from Bristol Myers Squibb Co., Ltd., Pfizer Japan Inc., and Nippontect systems Co. Ltd., Eiichi Tanaka Speakers bureau: ET has received lecture fees or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Celltrion Healthcare Japan CO, LTD., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kyowa Pharma Chemical CO., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical CO., Ltd., Nippon Kayaku Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd, and UCB Japan Co. Ltd., Tomohiro Kawabe: None declared, Katsunori Ikari: None declared, Masayoshi Harigai Speakers bureau: MH has received speaker’s fee from AbbVie Japan GK, Astra Zeneca K. K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Japan, Pfizer Japan Inc., CIMIC Holdings Co., Ltd., Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd and UCB Japan., Consultant of: MH is a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd., and Teijin Pharma., Grant/research support from: MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekisui Medical, Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd." @default.
• W4283711468 created "2022-06-30" @default.
• W4283711468 creator A5003556754 @default.
• W4283711468 creator A5009270103 @default.
• W4283711468 creator A5014443167 @default.
• W4283711468 creator A5015562826 @default.
• W4283711468 creator A5018787875 @default.
• W4283711468 creator A5032267003 @default.
• W4283711468 date "2022-05-23" @default.
• W4283711468 modified "2023-09-26" @default.
• W4283711468 title "POS1298 RELATIONSHIP BETWEEN DISEASE ACTIVITY BY JADAS-27, SDAI, AND DAS-28 AND SUBSEQUENT CHANGES IN PHYSICAL FUNCTION IN ADULT PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS" @default.
• W4283711468 doi "https://doi.org/10.1136/annrheumdis-2022-eular.981" @default.
• W4283711468 hasPublicationYear "2022" @default.
• W4283711468 type Work @default.
• W4283711468 citedByCount "0" @default.
• W4283711468 crossrefType "journal-article" @default.
• W4283711468 hasAuthorship W4283711468A5003556754 @default.
• W4283711468 hasAuthorship W4283711468A5009270103 @default.
• W4283711468 hasAuthorship W4283711468A5014443167 @default.
• W4283711468 hasAuthorship W4283711468A5015562826 @default.
• W4283711468 hasAuthorship W4283711468A5018787875 @default.
• W4283711468 hasAuthorship W4283711468A5032267003 @default.
• W4283711468 hasBestOaLocation W42837114681 @default.
• W4283711468 hasConcept C126322002 @default.
• W4283711468 hasConcept C1862650 @default.
• W4283711468 hasConcept C198451711 @default.
• W4283711468 hasConcept C2777077863 @default.
• W4283711468 hasConcept C2777575956 @default.
• W4283711468 hasConcept C2779134260 @default.
• W4283711468 hasConcept C2909065710 @default.
• W4283711468 hasConcept C71924100 @default.
• W4283711468 hasConceptScore W4283711468C126322002 @default.
• W4283711468 hasConceptScore W4283711468C1862650 @default.
• W4283711468 hasConceptScore W4283711468C198451711 @default.
• W4283711468 hasConceptScore W4283711468C2777077863 @default.
• W4283711468 hasConceptScore W4283711468C2777575956 @default.
• W4283711468 hasConceptScore W4283711468C2779134260 @default.
• W4283711468 hasConceptScore W4283711468C2909065710 @default.
• W4283711468 hasConceptScore W4283711468C71924100 @default.
• W4283711468 hasIssue "Suppl 1" @default.
• W4283711468 hasLocation W42837114681 @default.
• W4283711468 hasOpenAccess W4283711468 @default.
• W4283711468 hasPrimaryLocation W42837114681 @default.
• W4283711468 hasRelatedWork W1981471379 @default.
• W4283711468 hasRelatedWork W2001980429 @default.
• W4283711468 hasRelatedWork W2003239344 @default.
• W4283711468 hasRelatedWork W2097436305 @default.
• W4283711468 hasRelatedWork W2099861443 @default.
• W4283711468 hasRelatedWork W2410978906 @default.
• W4283711468 hasRelatedWork W3020467361 @default.
• W4283711468 hasRelatedWork W3031146099 @default.
• W4283711468 hasRelatedWork W3079246402 @default.
• W4283711468 hasRelatedWork W18291341 @default.
• W4283711468 hasVolume "81" @default.
• W4283711468 isParatext "false" @default.
• W4283711468 isRetracted "false" @default.
• W4283711468 workType "article" @default.